Next Article in Journal
A Familial Case of Multiple Endocrine Neoplasia 2A: From Morphology to Genetic Alterations Penetration in Three Generations of a Family
Next Article in Special Issue
Long-Term Results of Below-The-Knee Bypass Using a Prosthetic Graft with a Distal Arteriovenous Fistula Interposition
Previous Article in Journal
Novel Host Response-Based Diagnostics to Differentiate the Etiology of Fever in Patients Presenting to the Emergency Department
Previous Article in Special Issue
Comparison of Safety of RADial comPRESSion Devices: A Multi-Center Trial of Patent Hemostasis following Percutaneous Coronary Intervention from Conventional Radial Access (RAD-PRESS Trial)
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Factors Associated with Impaired Resistive Reserve Ratio and Microvascular Resistance Reserve

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan
*
Author to whom correspondence should be addressed.
Diagnostics 2023, 13(5), 950; https://doi.org/10.3390/diagnostics13050950
Submission received: 24 January 2023 / Revised: 22 February 2023 / Accepted: 1 March 2023 / Published: 2 March 2023
(This article belongs to the Special Issue New Techniques in Interventional Cardiology)

Abstract

:
Coronary microvascular dysfunction (CMD) is described as an important subset of ischemia with no obstructive coronary artery disease. Resistive reserve ratio (RRR) and microvascular resistance reserve (MRR) have been proposed as novel physiological indices evaluating coronary microvascular dilation function. The aim of this study was to explore factors associated with impaired RRR and MRR. Coronary physiological indices were invasively evaluated in the left anterior descending coronary artery using the thermodilution method in patients suspected of CMD. CMD was defined as a coronary flow reserve <2.0 and/or index of microcirculatory resistance ≥25. Of 117 patients, 26 (24.1%) had CMD. RRR (3.1 ± 1.9 vs. 6.2 ± 3.2, p < 0.001) and MRR (3.4 ± 1.9 vs. 6.9 ± 3.5, p < 0.001) were lower in the CMD group. In the receiver operating characteristic curve analysis, RRR (area under the curve 0.84, p < 0.001) and MRR (area under the curve 0.85, p < 0.001) were both predictive of the presence of CMD. In the multivariable analysis, previous myocardial infarction, lower hemoglobin, higher brain natriuretic peptide levels, and intracoronary nicorandil were identified as factors associated with lower RRR and MRR. In conclusion, the presence of previous myocardial infarction, anemia, and heart failure was associated with impaired coronary microvascular dilation function. RRR and MRR may be useful to identify patients with CMD.

1. Introduction

The traditional understanding is that epicardial coronary artery disease (CAD) plays a major role in ischemic heart disease, although previous registry data showed that only less than one-half of patients suspected of angina had significant lesions in epicardial coronary arteries [1,2]. In this context, ischemia with no obstructive CAD (INOCA) has been increasingly recognized as a major etiology of ischemic heart disease [3,4], in which coronary microvascular dysfunction (CMD) and vasospastic angina are described as important subsets of INOCA in the expert consensus document [5]. Since CMD reportedly deteriorates a patient’s quality of life and prognosis [3,6], accurate identification and diagnosis are clinically relevant. Coronary flow reserve (CFR), which is the ratio of hyperemic to resting blood flow, represents coronary blood flow capacity including epicardial coronary arteries and microvasculature to accommodate an increasing demand for oxygen at excise or stress [7]. Since reduced CFR indicates the presence of CMD when no significant epicardial CAD exists, the recent European and American guidelines recommend the measurement of CFR in patients suspected of INOCA [8,9]. CFR relies on resting flow for the calculation, and, thus, hemodynamic perturbation including a change in heart rate, blood pressure, and left ventricular contractility affects CFR value [10]. Recently, resistive reserve ratio (RRR) and microvascular resistance reserve (MRR) have been proposed as novel physiological indices to represent coronary microvascular dilation function [11,12]. Given that these indices take into account the information on coronary pressure as well as flow [11,12], RRR and MRR may better estimate coronary microvascular function as compared with CFR. Indeed, previous reports showed that RRR was superior to CFR in predicting future cardiovascular events in patients with CAD [13,14]. However, data are scarce on factors related to RRR and MRR. The aim of the present study was to explore factors associated with impaired RRR and MRR.

2. Materials and Methods

2.1. Study Population

This was a retrospective, single-center study at Chiba University Hospital. Between July 2020 and June 2022, a wire-based coronary physiological assessment was conducted on 117 patients who were suspected of having CMD due to their chest pain with no apparent epicardial CAD. The invasive physiological assessment was performed in the LAD. Patients with a physiological assessment in a nonelective setting (i.e., acute coronary syndrome) (n = 5) and missing data (n = 4) were excluded. In addition, patients with angiographically significant epicardial CAD (percentage of diameter stenosis on visual assessment >50%) in the LAD were also excluded. Thus, a total of 108 patients were included in the present analysis. This study was done in accordance with the Declaration of Helsinki. The ethics committee of the Chiba University Graduate School of Medicine approved this study (Approval number: M10348, date: 27 July 2022). Informed consent was obtained in the form of opt-out.

2.2. Invasive Coronary Physiological Assessment

The invasive diagnostic procedure is schematized in Figure 1. After the administration of intracoronary isosorbide dinitrate, a coronary angiography was performed per local standard practice [15,16]. In the present study, wire-based invasive coronary physiological indices were measured by the bolus-saline injection thermodilution method using a 6 Fr guiding catheter with no side holes [17,18]. After equalization, the pressure sensor guidewire (PressureWire X, Abbot Vascular, Santa Clara, USA) was advanced into the distal third of the LAD, and 3 milliliters of room-temperature saline were injected into the LAD at 3 times, automatically calculating mean transit time (Tmn) with a dedicated system (CoroFlow system, Coroventis Research, Uppsala, Sweden). Simultaneously, mean aortic pressure (Pa) and distal coronary pressure (Pd) were measured. Maximum hyperemia was induced by intracoronary administration of papaverine (12 mg) or nicorandil (2 mg) [16,19]. All indices of coronary pressure and flow (i.e., Tmn) were measured at resting and hyperemic conditions.
Multiple coronary physiological indices were evaluated in this study as follows: the ratio of Pd to Pa (resting Pd/Pa), fractional flow reserve (FFR), baseline resting index (BRI), index of microcirculatory resistance (IMR), CFR, RRR, and MRR, all of which were calculated using Pa, Pd, and Tmn at rest and hyperemia. FFR was defined as Pd/Pa at hyperemia. BRI and IMR, both of which represent a coronary microvascular tone, were defined as Pd multiplied by Tmn at resting and hyperemic conditions, respectively [13,14,20,21]. CFR was defined as resting Tmn divided by hyperemic Tmn. RRR, the ratio of microvascular tone at rest to that at hyperemia was defined as follows: RRR = BRI/IMR = (resting Pd × resting Tmn)/(hyperemic Pd × hyperemic Tmn) = CFR × (resting Pd/hyperemic Pd) [13,14]. In the present study, MRR was calculated by using indices obtained by a bolus-saline thermodilution method, rather than measured by absolute coronary blood flow using a continuous-saline thermodilution method. The definition of MRR was as follows: MRR = CFR × (resting Pa/hyperemic Pd) = (CFR/FFR) × (resting Pa/hyperemic Pa) = RRR × (resting Pa/resting Pd) [12,22]. The cut-off values for abnormal FFR, IMR, and CFR were determined as ≤0.80, ≥25, and <2.0, respectively [8,9]. In the present study, patients with abnormal CFR and/or IMR (i.e., CFR < 2.0 and/or IMR ≥ 25) were defined as having CMD [5,8,9].

2.3. Endpoints and Statistical Analysis

The primary interest of this study was to explore factors associated with impaired (i.e., lower) RRR and MRR. All statistical analyses were performed using JMP pro version 16.0 (SAS Institute Inc., Cary, CA, USA). Continuous variables were expressed as mean ± standard deviation and compared with the Student t-test. Categorical variables were expressed as frequency (%) and assessed with Fisher’s exact test. The normal distribution was visually evaluated with histograms. Due to the skewed distribution, a log transformation was performed to assess the level of brain natriuretic peptide (BNP). The receiver operating characteristic (ROC) curve analyses were performed to assess the best cut-off value of RRR and MRR for predicting CMD. Univariable and multivariable linear regression analyses were performed to explore factors related to coronary physiological indices. In the regression models, we included variables reportedly affecting coronary physiological statuses such as age, sex, body mass index, diabetes, hypertension, previous myocardial infarction (MI), renal function assessed with estimated glomerular filtration rate, anemia evaluated with a hemoglobin level, heart failure estimated by log-transformed BNP, and hyperemic agent (i.e., intracoronary papaverine versus nicorandil) [23,24,25,26,27,28,29,30,31,32]. The results of the regression analysis are displayed in a heat map. As a sensitivity analysis, the univariable and multivariable linear regression analyses were performed after excluding cases in which intracoronary nicorandil was used to achieve maximum hyperemia. A value of p < 0.05 was considered statistically significant. No corrections for multiple comparisons were performed.

3. Results

Of the 108 patients, 26 (24.1%) had CMD (Table 1). Baseline characteristics between patients with and without CMD are summarized in Table 1. Patients with CMD were more likely to be women, while other characteristics were similar between the two groups (Table 1).
Coronary physiological findings are shown in Table 2. To archive maximum hyperemia, intracoronary papaverine, and nicorandil were used in 62.0% and 38.0%, respectively. The use of nicorandil was more frequent in women than in men (79.3% vs. 22.8%, p < 0.001). FFR, BRI, and IMR were significantly higher and CFR, RRR, and MRR were lower in patients with CMD than those without (Table 2).
The ROC curve analyses showed that RRR and MRR were both predictive of the presence of CMD (Figure 2). With the best cut-off value, the sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy of RRR ≤ 3.4 and MRR ≤ 3.7 for CMD were 0.77, 0.84, 0.61, 0.92, and 0.82, and 0.77, 0.87, 0.65, 0.92, and 0.84, respectively.
In the univariable analysis, female gender, the presence of previous MI, a lower hemoglobin level, higher log-transformed BNP, and intracoronary nicorandil as a hyperemic agent were significantly associated with lower RRR and MRR (Figure 3).
Multivariable analysis indicated previous MI, a lower hemoglobin level, higher log-transformed BNP, and intracoronary nicorandil as predictors of lower RRR and MRR (Figure 4).
When excluding cases in which intracoronary nicorandil was used to achieve maximum hyperemia (Table 3 and Table 4), the overall results were similar (Figure 5, Figure 6 and Figure 7).

4. Discussion

The present study demonstrated that among patients suspected of CMD, approximately one quarter had invasively assessed CFR <2.0 and/or IMR ≥25. Patients with CMD had a lower CFR, RRR, and MRR than those without. Multivariable analysis identified previous MI, anemia, and heart failure as factors associated with impaired RRR and MRR. To our knowledge, this is the first report exploring predictors of the novel indices, RRR and MRR, for evaluating coronary microvascular dilation function.

4.1. RRR and MRR

Recently, INOCA has been of clinical interest, in which CMD is the main subset [5]. Since invasive identification and subsequent medical therapy were shown to improve the quality of life in patients with INOCA [33,34], an accurate diagnosis is clinically relevant. Although CFR (<2.0) and IMR (≥25) are suggested to define INOCA in the guidelines [8,9], whether the two indices can accurately identify patients with CMD remains uncertain. CFR is affected by hemodynamic perturbation such as a change in heart rate, blood pressure, and left ventricular contractility [10], and IMR is influenced by the amount of myocardium subtended to the location of the pressure-temperature sensor [35]. To overcome the limitations of CFR and IMR measurement, recently emerged RRR and MRR may be useful for evaluating coronary microvascular dilation function. While previous studies showed that only one physiologic index, including FFR, CFR, or IMR, was unable to fully discriminate patients at higher risks of clinical events, RRR is an integrated physiologic index of both coronary flow and pressure, potentially resulting in better risk stratification in CMD [13,14]. In fact, a previous single-center study (n = 1692) showed that RRR (mean value 2.88) was useful to stratify risks for all-cause mortality in patients with angina or ischemia and nonobstructive CAD, with the best cut-off value of 2.62 [14]. Another patient-level pooled cohort in Korea, Japan, and Spain demonstrated that lower RRR was associated with worse clinical outcomes in a stepwise manner and that even in patients with preserved FFR (>0.80) and CFR (>2.0), lower RRR (<3.5) was related to an increased risk of patient-oriented composite outcomes during the long-term follow-up [13]. The cut-off (median) value for predicting outcomes suggested in the pooled data (i.e., 3.5) was in line with that for the presence of CMD in the present study (i.e., 3.4), although RRR in the present study was numerically higher than that of previous studies [13,14]. In the prior pooled data, >30% of patients had CFR <2.0 [13], whereas approximately 10% did in the present study, suggesting that our study cohort represented relatively preserved coronary microvascular function.
MRR was originally developed as the index measured by absolute coronary blood flow with a continuous-saline thermodilution method using a dedicated microcatheter [36]. MRR is conceptually specific for microcirculation and independent of myocardial mass [12]. Although MRR was calculated by using indices obtained with a bolus-saline thermodilution method in the present study, it has the potential to avoid influence with epicardial CAD and the amount of myocardium [12]. The suggested cut-off value of MRR for the presence of CMD in this study (i.e., 3.7) was slightly higher than that of RRR, which may be reasonable due to the calculation formula (i.e., MRR = RRR × [resting Pa/resting Pd]) [12,22]. Given that CFR, RRR, and MRR were all significantly lower in patients with CMD than those without, multiple physiological assessments can aid in identifying patients with CMD. Further studies are needed to elucidate the cut-off values of RRR and MRR and whether the novel indices are superior to conventional invasive indices such as CFR and IMR in estimating coronary microvascular function.

4.2. Factors Associated with RRR and MRR

It is conceivable that CMD, greater resting coronary blood flow, or both result in impaired microvascular dilation response (i.e., RRR and MRR) [13,14], which are reportedly associated with several clinical and procedural factors. For instance, FFR was preserved while IMR, CFR, RRR, and MRR were more impaired in women than in men in the univariable analysis in the present study, probably due to the longer hyperemic Tmn (slower coronary blood flow) (Figure 3). However, previous studies showed that women had lower CFR, with a shorter resting Tmn (faster coronary blood flow) [37,38]. The longer hyperemic Tmn in women may be confounded with the higher likelihood of nicorandil use as a hyperemic agent. Indeed, when excluding cases in which maximum hyperemia was achieved by intracoronary nicorandil, the female gender was no longer associated with lower CFR, RRR, and MRR in both univariable and multivariable analyses (Figure 6 and Figure 7). Women are likely to have impaired CFR, though the underlying mechanisms remain unclear. Additionally, a previous study in which prognostic implications of RRR were evaluated in patients with INOCA showed that the rate of women was higher in patients with reduced RRR (<2.62) than in their counterparts [14]. In the multivariable adjustment with hemoglobin and BNP levels, female gender was no longer a significant factor associated with CFR, RRR, and MRR in the present study, suggesting that anemia may play a role in a higher likelihood of CMD in women. Apart from gender differences, several patient characteristics such as older age and the presence of diabetes are known to be associated with impaired CFR [24,39]. A recent retrospective study showed that MRR was significantly lower in diabetic patients with suspected angina and nonobstructive CAD than those without diabetes [31], and diabetes was also reportedly associated with lower RRR [13,14]. Although the present study did not show the direct relation of diabetes to CFR, the multivariable analysis indicated that patients with diabetes had nonsignificantly lower RRR and MRR.
In this study, a multivariable analysis identified previous MI, anemia, and heart failure as factors associated with impaired RRR and MRR. In a recent prospective study in which invasive measures of coronary microvascular function such as CFR and IMR were repeatedly evaluated in patients undergoing primary percutaneous coronary artery intervention for ST-segment-elevation MI, IMR remained high (i.e., 25.6 ± 17.8) at one month after the index event [40]. Patients with a history of MI are likely to have coronary arteriosclerosis and impaired microvascular function [41], probably resulting in lower RRR and MRR. The increased resting and impaired hyperemic coronary blood flow in patients with anemia and heart failure were reported in previous investigations, as shown in the present study [42,43,44], supported by the fact that lower hemoglobin and higher BNP levels were associated with a shorter resting Tmn and BRI in the univariable models (Figure 3). It is conceivable that the increased resting coronary blood flow reflected a patient condition where hyperemic status, at least partially, was achieved even at rest, preventing “additional” maximum hyperemia by intracoronary administration of papaverine and nicorandil. Although intracoronary nicorandil is safe and effective to induce hyperemia [19], an achievable hyperemic effect by intracoronary papaverine may be greater as compared with nicorandil [32], leading to the significant influence of different hyperemic agents (i.e., papaverine vs. nicorandil) on RRR and MRR. In previous reports, a hyperemic effect of intracoronary papaverine is induced earlier and lasts longer than that of nicorandil [45,46]. However, when excluding cases in which nicorandil was used for inducing maximum hyperemia, the overall results were similar. Thus, we believe that the presence of previous MI, anemia, and heart failure may be significant predictors of impaired RRR and MRR. To estimate whether a patient has CMD in clinical practice, these factors may be taken into account.

4.3. Study Limitations

There were some limitations in the present study. This was a retrospective, single-center, observational study, and the sample size was modest. The number of patients included in this study may be acceptable to perform the multivariable analyses [47], however, a larger sample size would be preferred. Although the present study included patients suspected of CMD, only one quarter had CFR <2.0 and/or IMR ≥25. Noninvasive stress tests to evaluate myocardial ischemia were not performed in a uniform manner and thus, the data were not available. Different hyperemic agents, such as intracoronary papaverine, nicorandil, intravenous adenosine, and adenosine triphosphate reportedly have different characteristics in safety, efficacy, and availability in real-world clinical practice. The decision of physiological measurement and the selection of hyperemic agent were left to the operator′s discretion. Even though the sensitivity analysis confirmed similar results between the entire study population and cases in which intracoronary papaverine was used to achieve maximum hyperemia, a selection bias is possible. In this study, we estimated MRR by using a bolus-saline thermodilution method rather than using a continuous-saline thermodilution method as done in previous reports [12,22].

5. Conclusions

Coronary microvascular dilation function assessed with RRR and MRR was impaired in patients with CMD, both of which may help estimate coronary microvascular function. The presence of previous MI, anemia, and heart failure were identified as factors associated with lower RRR and MRR. The clinical usefulness of RRR and MRR beyond conventional physiological indices such as CFR and IMR deserves further investigation.

Author Contributions

Conceptualization, T.Y. and Y.S.; methodology, T.Y. and Y.S.; formal analysis, T.Y.; investigation, T.Y. and Y.S. resources, T.Y., D.Y. and Y.S.; data curation, T.Y. and Y.S.; writing—original draft preparation, T.Y.; writing—review and editing, Y.S., H.K. and Y.K.; visualization, T.Y. and Y.S.; supervision, Y.K.; project administration, Y.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Chiba University Graduate School of Medicine (Approval number: M10348, date: 27 July 2022).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study in the form of an opt out.

Data Availability Statement

The data of this study are available upon reasonable request.

Conflicts of Interest

Yoshio Kobayashi reports research grants from Abbott Medical Japan. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

References

  1. Patel, M.R.; Peterson, E.D.; Dai, D.; Brennan, J.M.; Redberg, R.F.; Anderson, H.V.; Brindis, R.G.; Douglas, P.S. Low diagnostic yield of elective coronary angiography. N. Engl. J. Med. 2010, 362, 886–895. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Reeh, J.; Therming, C.B.; Heitmann, M.; Højberg, S.; Sørum, C.; Bech, J.; Husum, D.; Dominguez, H.; Sehestedt, T.; Hermann, T.; et al. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina. Eur. Heart J. 2019, 40, 1426–1435. [Google Scholar] [CrossRef] [PubMed]
  3. Beltrame, J.F.; Tavella, R.; Jones, D.; Zeitz, C. Management of ischaemia with non-obstructive coronary arteries (INOCA). BMJ. 2021, 375, e060602. [Google Scholar] [CrossRef] [PubMed]
  4. Ford, T.J.; Ong, P.; Sechtem, U.; Beltrame, J.; Camici, P.G.; Crea, F.; Kaski, J.C.; Bairey Merz, C.N.; Pepine, C.J.; Shimokawa, H.; et al. Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When. JACC Cardiovasc. Interv. 2020, 13, 1847–1864. [Google Scholar] [CrossRef] [PubMed]
  5. Kunadian, V.; Chieffo, A.; Camici, P.G.; Berry, C.; Escaned, J.; Maas, A.H.E.M.; Prescott, E.; Karam, N.; Appelman, Y.; Fraccaro, C.; et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. EuroIntervention 2021, 16, 1049–1069. [Google Scholar] [PubMed]
  6. Schumann, C.L.; Mathew, R.C.; Dean, J.L.; Yang, Y.; Balfour, P.C., Jr.; Shaw, P.W.; Robinson, A.A.; Salerno, M.; Kramer, C.M.; Bourque, J.M. Functional and Economic Impact of INOCA and Influence of Coronary Microvascular Dysfunction. JACC Cardiovasc. Imaging 2021, 14, 1369–1379. [Google Scholar] [CrossRef] [PubMed]
  7. Gould, K.L.; Lipscomb, K.; Hamilton, G.W. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am. J. Cardiol. 1974, 33, 87–94. [Google Scholar] [CrossRef] [PubMed]
  8. Knuuti, J.; Wijns, W.; Saraste, A.; Capodanno, D.; Barbato, E.; Funck-Brentano, C.; Prescott, E.; Storey, R.F.; Deaton, C.; Cuisset, T.; et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2020, 41, 407–477. [Google Scholar] [CrossRef] [Green Version]
  9. Gulati, M.; Levy, P.D.; Mukherjee, D.; Amsterdam, E.; Bhatt, D.L.; Birtcher, K.K.; Blankstein, R.; Boyd, J.; Bullock-Palmer, R.P.; Conejo, T.; et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021, 144, e368–e454. [Google Scholar]
  10. De Bruyne, B.; Bartunek, J.; Sys, S.U.; Pijls, N.H.; Heyndrickx, G.R.; Wijns, W. Simultaneous coronary pressure and flow velocity measurements in humans. Feasibility, reproducibility, and hemodynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope index, and fractional flow reserve. Circulation 1996, 94, 1842–1849. [Google Scholar] [CrossRef]
  11. Layland, J.; Carrick, D.; McEntegart, M.; Ahmed, N.; Payne, A.; McClure, J.; Sood, A.; McGeoch, R.; MacIsaac, A.; Whitbourn, R.; et al. Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with non-ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 2013, 6, 231–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. De Bruyne, B.; Pijls, N.H.J.; Gallinoro, E.; Candreva, A.; Fournier, S.; Keulards, D.C.J.; Sonck, J.; Van’t Veer, M.; Barbato, E.; Bartunek, J.; et al. Microvascular Resistance Reserve for Assessment of Coronary Microvascular Function: JACC Technology Corner. J. Am. Coll. Cardiol. 2021, 78, 1541–1549. [Google Scholar] [CrossRef] [PubMed]
  13. Lee, S.H.; Lee, J.M.; Park, J.; Choi, K.H.; Hwang, D.; Doh, J.H.; Nam, C.W.; Shin, E.S.; Hoshino, M.; Murai, T.; et al. Prognostic Implications of Resistive Reserve Ratio in Patients With Coronary Artery Disease. J. Am. Heart Assoc. 2020, 9, e015846. [Google Scholar] [CrossRef] [PubMed]
  14. Toya, T.; Ahmad, A.; Corban, M.T.; Özcan, I.; Sara, J.D.; Sebaali, F.; Escaned, J.; Lerman, L.O.; Lerman, A. Risk Stratification of Patients With NonObstructive Coronary Artery Disease Using Resistive Reserve Ratio. J. Am. Heart Assoc. 2021, 10, e020464. [Google Scholar] [CrossRef]
  15. Sawano, M.; Yamaji, K.; Kohsaka, S.; Inohara, T.; Numasawa, Y.; Ando, H.; Iida, O.; Shinke, T.; Ishii, H.; Amano, T. Contemporary use and trends in percutaneous coronary intervention in Japan: An outline of the J-PCI registry. Cardiovasc. Interv. Ther. 2020, 35, 218–226. [Google Scholar] [CrossRef]
  16. Kawase, Y.; Matsuo, H.; Kuramitsu, S.; Shiono, Y.; Akasaka, T.; Tanaka, N.; Amano, T.; Kozuma, K.; Nakamura, M.; Yokoi, H.; et al. Clinical use of physiological lesion assessment using pressure guidewires: An expert consensus document of the Japanese association of cardiovascular intervention and therapeutics-update 2022. Cardiovasc. Interv. Ther. 2022, 37, 425–439. [Google Scholar] [CrossRef]
  17. Yamazaki, T.; Nishi, T.; Saito, Y.; Tateishi, K.; Kato, K.; Kitahara, H.; Kobayashi, Y. Discrepancy between plaque vulnerability and functional severity of angiographically intermediate coronary artery lesions. Cardiovasc. Interv. Ther. 2022, 37, 691–698. [Google Scholar] [CrossRef]
  18. Murasato, Y.; Kinoshita, Y.; Shite, J.; Hikichi, Y.; Nam, C.W.; Koo, B.K. Difference in basic concept of coronary bifurcation intervention between Korea and Japan. Insight from questionnaire in experts of Korean and Japanese bifurcation clubs. Cardiovasc. Interv. Ther. 2022, 37, 89–100. [Google Scholar] [CrossRef]
  19. Jang, H.J.; Koo, B.K.; Lee, H.S.; Park, J.B.; Kim, J.H.; Seo, M.K.; Yang, H.M.; Park, K.W.; Nam, C.W.; Doh, J.H.; et al. Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory. Eur. Heart J. 2013, 34, 2055–2062. [Google Scholar] [CrossRef] [Green Version]
  20. Nishi, T.; Kitahara, H.; Saito, Y.; Nishi, T.; Nakayama, T.; Fujimoto, Y.; Matsumiya, G.; Kobayashi, Y. Invasive assessment of microvascular function in patients with valvular heart disease. Coron. Artery Dis. 2018, 29, 223–229. [Google Scholar] [CrossRef]
  21. Saito, Y.; Kitahara, H.; Nishi, T.; Fujimoto, Y.; Kobayashi, Y. Decreased resting coronary flow and impaired endothelial function in patients with vasospastic angina. Coron. Artery Dis. 2019, 30, 291–296. [Google Scholar] [CrossRef] [PubMed]
  22. Saito, Y.; Nishi, T.; Kato, K.; Kitahara, H.; Kobayashi, Y. Resistive reserve ratio and microvascular resistance reserve in patients with coronary vasospastic angina. Heart Vessels 2022, 37, 1489–1495. [Google Scholar] [CrossRef]
  23. Crea, F.; Camici, P.G.; Bairey Merz, C.N. Coronary microvascular dysfunction: An update. Eur. Heart J. 2014, 35, 1101–1111. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Nahser, P.J., Jr.; Brown, R.E.; Oskarsson, H.; Winniford, M.D.; Rossen, J.D. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 1995, 91, 635–640. [Google Scholar] [CrossRef] [PubMed]
  25. Wessel, T.R.; Arant, C.B.; McGorray, S.P.; Sharaf, B.L.; Reis, S.E.; Kerensky, R.A.; von Mering, G.O.; Smith, K.M.; Pauly, D.F.; Handberg, E.M.; et al. Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: Results from the NHLBI Women’s Ischemia Syndrome Evaluation (WISE). Clin. Cardiol. 2007, 30, 69–74. [Google Scholar] [CrossRef] [PubMed]
  26. Selthofer-Relatić, K.; Bošnjak, I.; Kibel, A. Obesity Related Coronary Microvascular Dysfunction: From Basic to Clinical Practice. Cardiol. Res. Pract. 2016, 2016, 8173816. [Google Scholar] [CrossRef] [Green Version]
  27. Antony, I.; Nitenberg, A.; Foult, J.M.; Aptecar, E. Coronary vasodilator reserve in untreated and treated hypertensive patients with and without left ventricular hypertrophy. J. Am. Coll. Cardiol. 1993, 22, 514–520. [Google Scholar] [CrossRef] [Green Version]
  28. Konijnenberg, L.S.F.; Damman, P.; Duncker, D.J.; Kloner, R.A.; Nijveldt, R.; van Geuns, R.M.; Berry, C.; Riksen, N.P.; Escaned, J.; van Royen, N. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovasc. Res. 2020, 116, 787–805. [Google Scholar] [CrossRef]
  29. Östlund-Papadogeorgos, N.; Ekenbäck, C.; Jokhaji, F.; Mir-Akbari, H.; Witt, N.; Jernberg, T.; Wallén, H.; Linder, R.; Törnerud, M.; Samad, B.A.; et al. Blood haemoglobin, renal insufficiency, fractional flow reserve and plasma NT-proBNP is associated with index of microcirculatory resistance in chronic coronary syndrome. Int. J. Cardiol. 2020, 317, 1–6. [Google Scholar] [CrossRef]
  30. Neishi, Y.; Akasaka, T.; Tsukiji, M.; Kume, T.; Wada, N.; Watanabe, N.; Kawamoto, T.; Kaji, S.; Yoshida, K. Reduced coronary flow reserve in patients with congestive heart failure assessed by transthoracic Doppler echocardiography. J. Am. Soc. Echocardiogr. 2005, 18, 15–19. [Google Scholar] [CrossRef]
  31. Gallinoro, E.; Paolisso, P.; Candreva, A.; Bermpeis, K.; Fabbricatore, D.; Esposito, G.; Bertolone, D.; Fernandez Peregrina, E.; Munhoz, D.; Mileva, N.; et al. Microvascular Dysfunction in Patients With Type II Diabetes Mellitus: Invasive Assessment of Absolute Coronary Blood Flow and Microvascular Resistance Reserve. Front. Cardiovasc. Med. 2021, 8, 765071. [Google Scholar] [CrossRef] [PubMed]
  32. Matsumoto, H.; Mikuri, M.; Masaki, R.; Tanaka, H.; Ogura, K.; Arai, T.; Sakai, R.; Oishi, Y.; Okada, N.; Shinke, T. Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine. Int. J. Cardiol. 2020, 314, 1–6. [Google Scholar] [CrossRef] [PubMed]
  33. Ford, T.J.; Stanley, B.; Good, R.; Rocchiccioli, P.; McEntegart, M.; Watkins, S.; Eteiba, H.; Shaukat, A.; Lindsay, M.; Robertson, K.; et al. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J. Am. Coll. Cardiol. 2018, 72, 2841–2855. [Google Scholar] [CrossRef]
  34. Ford, T.J.; Stanley, B.; Sidik, N.; Good, R.; Rocchiccioli, P.; McEntegart, M.; Watkins, S.; Eteiba, H.; Shaukat, A.; Lindsay, M.; et al. 1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). JACC Cardiovasc. Interv. 2020, 13, 33–45. [Google Scholar] [CrossRef]
  35. Echavarría-Pinto, M.; van de Hoef, T.P.; Nijjer, S.; Gonzalo, N.; Nombela-Franco, L.; Ibañez, B.; Sen, S.; Petraco, R.; Jimenez-Quevedo, P.; Nuñez-Gil, I.J.; et al. Influence of the amount of myocardium subtended to a coronary stenosis on the index of microcirculatory resistance. Implications for the invasive assessment of microcirculatory function in ischaemic heart disease. EuroIntervention 2017, 13, 944–952. [Google Scholar] [CrossRef] [PubMed]
  36. van ‘t Veer, M.; Adjedj, J.; Wijnbergen, I.; Tóth, G.G.; Rutten, M.C.; Barbato, E.; van Nunen, L.X.; Pijls, N.H.; De Bruyne, B. Novel monorail infusion catheter for volumetric coronary blood flow measurement in humans: In vitro validation. EuroIntervention 2016, 12, 701–707. [Google Scholar] [CrossRef] [PubMed]
  37. Kobayashi, Y.; Fearon, W.F.; Honda, Y.; Tanaka, S.; Pargaonkar, V.; Fitzgerald, P.J.; Lee, D.P.; Stefanick, M.; Yeung, A.C.; Tremmel, J.A. Effect of Sex Differences on Invasive Measures of Coronary Microvascular Dysfunction in Patients With Angina in the Absence of Obstructive Coronary Artery Disease. JACC Cardiovasc. Interv. 2015, 8, 1433–1441. [Google Scholar] [CrossRef] [Green Version]
  38. Chung, J.H.; Lee, K.E.; Lee, J.M.; Her, A.Y.; Kim, C.H.; Choi, K.H.; Song, Y.B.; Hahn, J.Y.; Kim, H.Y.; Choi, J.H.; et al. Effect of Sex Difference of Coronary Microvascular Dysfunction on Long-Term Outcomes in Deferred Lesions. JACC Cardiovasc. Interv. 2020, 13, 1669–1679. [Google Scholar] [CrossRef] [PubMed]
  39. Stegehuis, V.E.; Wijntjens, G.W.M.; Bax, M.; Meuwissen, M.; Chamuleau, S.A.J.; Voskuil, M.; Koch, K.T.; Di Mario, C.; Vrints, C.; Haude, M.; et al. Impact of clinical and haemodynamic factors on coronary flow reserve and invasive coronary flow capacity in non-obstructed coronary arteries: A patient-level pooled analysis of the DEBATE and ILIAS studies. EuroIntervention 2021, 16, e1503–e1510. [Google Scholar] [CrossRef]
  40. Demirkiran, A.; Robbers, L.F.H.J.; van der Hoeven, N.W.; Everaars, H.; Hopman, L.H.G.A.; Janssens, G.N.; Berkhof, H.J.; Lemkes, J.S.; van de Bovenkamp, A.A.; van Leeuwen, M.A.H.; et al. The Dynamic Relationship Between Invasive Microvascular Function and Microvascular Injury Indicators, and Their Association With Left Ventricular Function and Infarct Size at 1-Month After Reperfused ST-Segment-Elevation Myocardial Infarction. Circ. Cardiovasc. Interv. 2022, 15, 892–902. [Google Scholar] [CrossRef]
  41. Lee, J.M.; Layland, J.; Jung, J.H.; Lee, H.J.; Echavarria-Pinto, M.; Watkins, S.; Yong, A.S.; Doh, J.H.; Nam, C.W.; Shin, E.S.; et al. Integrated physiologic assessment of ischemic heart disease in real-world practice using index of microcirculatory resistance and fractional flow reserve: Insights from the International Index of Microcirculatory Resistance Registry. Circ. Cardiovasc. Interv. 2015, 8, e002857. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Scheel, K.W.; Brody, D.A.; Ingram, L.A.; Keller, F. Effects of chronic anemia on the coronary and coronary collateral vasculature in dogs. Circ. Res. 1976, 38, 553–559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Hoffman, J.I.; Spaan, J.A. Pressure-flow relations in coronary circulation. Physiol Rev. 1990, 70, 331–390. [Google Scholar] [CrossRef] [PubMed]
  44. Heusch, G. Coronary blood flow in heart failure: Cause, consequence and bystander. Basic Res. Cardiol. 2022, 117, 1. [Google Scholar] [CrossRef] [PubMed]
  45. Lee, J.M.; Kato, D.; Oi, M.; Toyofuku, M.; Takashima, H.; Waseda, K.; Amano, T.; Kurita, A.; Ishihara, H.; Lim, W.H.; et al. Safety and efficacy of intracoronary nicorandil as hyperaemic agent for invasive physiological assessment: A patient-level pooled analysis. EuroIntervention 2016, 12, e208–e215. [Google Scholar] [CrossRef] [Green Version]
  46. Mizukami, T.; Sonck, J.; Gallinoro, E.; Kodeboina, M.; Canvedra, A.; Nagumo, S.; Bartunek, J.; Wyffels, E.; Vanderheyden, M.; Shinke, T.; et al. Duration of Hyperemia With Intracoronary Administration of Papaverine. J. Am. Heart Assoc. 2021, 10, e018562. [Google Scholar] [CrossRef]
  47. Austin, P.C.; Steyerberg, E.W. The number of subjects per variable required in linear regression analyses. J. Clin. Epidemiol. 2015, 68, 627–636. [Google Scholar] [CrossRef] [Green Version]
Figure 1. After administration of ISDN, coronary angiography was performed. Subsequently, the pressure sensor guidewire (PressureWire X, Abbot Vascular, Santa Clara, CA, USA) was advanced into the distal third of the left anterior descending artery after equalization. Three milliliters of room-temperature saline were injected into the left anterior descending artery at 3 times at rest, automatically calculating Tmn. Mean Pa and Pd were measured simultaneously. Tmn, Pa, and Pd were again measured under maximum hyperemia using intracoronary papaverine or nicorandil. Pd/Pa at rest, FFR, CFR, BRI, IMR, RRR, and MRR were calculated. A blue arrow indicates the pressure sensor guidewire. BRI, baseline resistance index; CFR, coronary flow reserve; FFR, fractional flow reserve; IC, intracoronary; IMR, index of microcirculatory resistance; ISDN, intracoronary isosorbide dinitrate; MRR, microvascular resistance reserve; Pa, mean aortic pressure; Pd, mean distal coronary pressure; RRR, resistance reserve ratio; Tmn, mean transit time.
Figure 1. After administration of ISDN, coronary angiography was performed. Subsequently, the pressure sensor guidewire (PressureWire X, Abbot Vascular, Santa Clara, CA, USA) was advanced into the distal third of the left anterior descending artery after equalization. Three milliliters of room-temperature saline were injected into the left anterior descending artery at 3 times at rest, automatically calculating Tmn. Mean Pa and Pd were measured simultaneously. Tmn, Pa, and Pd were again measured under maximum hyperemia using intracoronary papaverine or nicorandil. Pd/Pa at rest, FFR, CFR, BRI, IMR, RRR, and MRR were calculated. A blue arrow indicates the pressure sensor guidewire. BRI, baseline resistance index; CFR, coronary flow reserve; FFR, fractional flow reserve; IC, intracoronary; IMR, index of microcirculatory resistance; ISDN, intracoronary isosorbide dinitrate; MRR, microvascular resistance reserve; Pa, mean aortic pressure; Pd, mean distal coronary pressure; RRR, resistance reserve ratio; Tmn, mean transit time.
Diagnostics 13 00950 g001
Figure 2. The receiver operating characteristic curve analyses of RRR and MRR for CMD. AUC, area under the curve; CMD, coronary microvascular dysfunction; MRR, microvascular resistance reserve, RRR; resistance reserve ratio.
Figure 2. The receiver operating characteristic curve analyses of RRR and MRR for CMD. AUC, area under the curve; CMD, coronary microvascular dysfunction; MRR, microvascular resistance reserve, RRR; resistance reserve ratio.
Diagnostics 13 00950 g002
Figure 3. A heat map for univariable linear regression analyses. A cell in light blue indicates no significant association (p ≥ 0.05). When significant associations are found (p < 0.05), cells are displayed in light (−0.20 ≤ r ≤ 0.20) or warm yellow (−0.30 ≤ r < −0.20 or 0.20 < r ≤ 0.30) or red (r < −0.30 or r > 0.30). BMI, body mass index; BNP, brain natriuretic peptide; BRI, baseline resistance index; CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MI, myocardial infarction; MRR, microvascular resistance reserve; Pd/Pa, ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Figure 3. A heat map for univariable linear regression analyses. A cell in light blue indicates no significant association (p ≥ 0.05). When significant associations are found (p < 0.05), cells are displayed in light (−0.20 ≤ r ≤ 0.20) or warm yellow (−0.30 ≤ r < −0.20 or 0.20 < r ≤ 0.30) or red (r < −0.30 or r > 0.30). BMI, body mass index; BNP, brain natriuretic peptide; BRI, baseline resistance index; CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MI, myocardial infarction; MRR, microvascular resistance reserve; Pd/Pa, ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Diagnostics 13 00950 g003
Figure 4. A heat map for multivariable linear regression analyses. A cell in light blue indicates no significant association (p ≥ 0.05). When significant associations are found (p < 0.05), cells are displayed in light (−0.20 ≤ β ≤ 0.20) or warm yellow (−0.30 ≤ β < −0.20 or 0.20 < β ≤ 0.30) or red (β < −0.30 or β > 0.30). BMI, body mass index; BNP, brain natriuretic peptide; BRI, baseline resistance index; CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MI, myocardial infarction; MRR, microvascular resistance reserve; Pd/Pa, ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Figure 4. A heat map for multivariable linear regression analyses. A cell in light blue indicates no significant association (p ≥ 0.05). When significant associations are found (p < 0.05), cells are displayed in light (−0.20 ≤ β ≤ 0.20) or warm yellow (−0.30 ≤ β < −0.20 or 0.20 < β ≤ 0.30) or red (β < −0.30 or β > 0.30). BMI, body mass index; BNP, brain natriuretic peptide; BRI, baseline resistance index; CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MI, myocardial infarction; MRR, microvascular resistance reserve; Pd/Pa, ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Diagnostics 13 00950 g004
Figure 5. The receiver operating characteristic curve analyses of RRR and MRR for CMD in cases in which papaverine was used as a hyperemic agent. AUC, area under the curve; CMD, coronary microvascular dysfunction; MRR, microvascular resistance reserve, RRR; resistance reserve ratio.
Figure 5. The receiver operating characteristic curve analyses of RRR and MRR for CMD in cases in which papaverine was used as a hyperemic agent. AUC, area under the curve; CMD, coronary microvascular dysfunction; MRR, microvascular resistance reserve, RRR; resistance reserve ratio.
Diagnostics 13 00950 g005
Figure 6. A heat map for univariable linear regression analyses in cases in which papaverine was used as a hyperemic agent. A cell in light blue indicates no significant association (p ≥ 0.05). When significant associations are found (p < 0.05), cells are displayed in light (−0.20 ≤ r ≤ 0.20) or warm yellow (−0.30 ≤ r < −0.20 or 0.20< r ≤ 0.30) or red (r < −0.30 or r > 0.30). BMI, body mass index; BNP, brain natriuretic peptide; BRI, baseline resistance index; CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MI, myocardial infarction; MRR, microvascular resistance reserve; Pd/Pa, ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Figure 6. A heat map for univariable linear regression analyses in cases in which papaverine was used as a hyperemic agent. A cell in light blue indicates no significant association (p ≥ 0.05). When significant associations are found (p < 0.05), cells are displayed in light (−0.20 ≤ r ≤ 0.20) or warm yellow (−0.30 ≤ r < −0.20 or 0.20< r ≤ 0.30) or red (r < −0.30 or r > 0.30). BMI, body mass index; BNP, brain natriuretic peptide; BRI, baseline resistance index; CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MI, myocardial infarction; MRR, microvascular resistance reserve; Pd/Pa, ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Diagnostics 13 00950 g006
Figure 7. A heat map for multivariable linear regression analyses in cases in which papaverine was used as a hyperemic agent. A cell in light blue indicates no significant association (p ≥ 0.05). When significant associations are found (p < 0.05), cells are displayed in light (−0.20 ≤ β ≤ 0.20) or warm yellow (−0.30 ≤ β < −0.20 or 0.20 < β ≤ 0.30) or red (β <−0.30 or β > 0.30). BMI, body mass index; BNP, brain natriuretic peptide; BRI, baseline resistance index; CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MI, myocardial infarction; MRR, microvascular resistance reserve; Pd/Pa, ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Figure 7. A heat map for multivariable linear regression analyses in cases in which papaverine was used as a hyperemic agent. A cell in light blue indicates no significant association (p ≥ 0.05). When significant associations are found (p < 0.05), cells are displayed in light (−0.20 ≤ β ≤ 0.20) or warm yellow (−0.30 ≤ β < −0.20 or 0.20 < β ≤ 0.30) or red (β <−0.30 or β > 0.30). BMI, body mass index; BNP, brain natriuretic peptide; BRI, baseline resistance index; CFR, coronary flow reserve; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MI, myocardial infarction; MRR, microvascular resistance reserve; Pd/Pa, ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Diagnostics 13 00950 g007
Table 1. Baseline characteristics.
Table 1. Baseline characteristics.
VariableAll
(n = 108)
CMD
(n = 26)
Non-CMD
(n = 82)
p Value
Age (years)68.5 ± 11.867.3 ± 13.068.9 ± 11.50.56
Men79 (73.1%)14 (53.9%)65 (79.3%)0.02
Body mass index (kg/m2)24.4 ± 3.624.6 ± 4.324.4 ± 3.40.78
Hypertension74 (68.5%)18 (69.2%)56 (68.3%)1.00
Diabetes31 (28.7%)8 (30.8%)23 (28.1%)0.81
Dyslipidemia85 (78.7%)19 (73.1%)66 (80.5%)0.42
Current smoking14 (13.0%)4 (15.4%)10 (12.2%)0.74
Chronic kidney disease37 (34.3%)13 (50.0%)24 (29.3%)0.06
Hemodialysis7 (6.5%)4 (15.4%)3 (3.7%)0.06
Previous MI12 (11.1%)2 (7.7%)10 (12.2%)0.73
Atrial fibrillation14 (13.0%)1 (3.9%)13 (15.9%)0.18
Hemoglobin (g/dL)13.7 ± 1.913.1 ± 2.113.9 ± 1.90.09
eGFR (mL/min/1.73 m2)65.5 ± 23.559.1 ± 29.367.6 ± 21.20.11
LDL cholesterol (mg/dL)96 ± 3190 ± 2398 ± 330.29
Glycated hemoglobin (%)6.0 ± 0.76.3 ± 1.06.0 ± 0.60.06
Log-BNP3.47 ± 1.353.89 ± 1.503.34 ± 1.230.08
Medical treatment
Antiplatelet agent59 (54.6%)13 (50.0%)46 (56.1%)0.65
Statin69 (63.9%)18 (69.2%)51 (62.2%)0.64
β-blocker37 (34.3%)9 (34.6%)28 (34.2%)1.00
ACE-i or ARB46 (42.6%)10 (38.5%)36 (43.9%)0.66
Calcium channel blocker57 (52.8%)15 (57.7%)42 (51.2%)0.65
Nitrate18 (16.7%)7 (26.9%)11 (13.4%)0.13
ACE-i, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP, brain natriuretic peptide; CMD, coronary microvascular dysfunction; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; MI, myocardial infarction.
Table 2. Physiological findings.
Table 2. Physiological findings.
VariableAll
(n = 108)
CMD
(n = 26)
Non-CMD
(n = 82)
p Value
Hyperemic agent
Papaverine67 (62.0%)11 (42.3%)56 (68.3%)0.02
Nicorandil41 (38.0%)15 (57.7%)26 (31.7%)
Physiologic findings
Resting Pd/Pa0.93 ± 0.030.93 ± 0.040.93 ± 0.020.75
FFR0.86 ± 0.060.89 ± 0.060.86 ± 0.060.04
FFR ≤ 0.8019 (17.6%)3 (11.5%)16 (19.5%)0.55
Resting Tmn0.94 ± 0.491.06 ± 0.670.91 ± 0.410.17
Hyperemic Tmn0.24 ± 0.150.40 ± 0.190.19 ± 0.08<0.001
BRI80.4 ± 43.399.0 ± 63.374.5 ± 33.00.01
IMR17.7 ± 11.531.5 ± 14.413.3 ± 5.5<0.001
IMR ≥2520 (18.5%)20 (76.9%)0 (0.0%)<0.001
CFR4.7 ± 2.62.8 ± 1.75.3 ± 2.5<0.001
CFR <2.012 (11.1%)12 (46.2%)0 (0.0%)<0.001
RRR5.5 ± 3.23.1 ± 1.96.2 ± 3.2<0.001
MRR6.1 ± 3.53.4 ± 1.96.9 ± 3.5<0.001
BRI, baseline resistance index; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MRR, microvascular resistance reserve; Pd/Pa, the ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Table 3. Baseline characteristics in patients with physiological testing using papaverine.
Table 3. Baseline characteristics in patients with physiological testing using papaverine.
VariableAll
(n = 67)
CMD
(n = 11)
Non-CMD
(n = 56)
p Value
Age (years)68.6 ± 11.667.3 ± 13.368.8 ± 11.30.68
Men61 (91.0%)10 (90.9%)51 (91.1%)1.00
Body mass index (kg/m2)24.9 ± 3.525.3 ± 3.824.8 ± 3.40.69
Hypertension49 (73.1%)8 (72.7%)41 (73.2%)1.00
Diabetes19 (28.4%)3 (27.3%)16 (28.6%)1.00
Dyslipidemia52 (77.6%)7 (63.6%)45 (80.4%)0.25
Current smoking12 (17.9%)3 (27.3%)9 (16.1%)0.40
Chronic kidney disease21 (31.3%)7 (63.6%)14 (25.0%)0.03
Hemodialysis6 (9.0%)3 (27.3%)3 (5.4%)0.051
Previous MI10 (14.9%)0 (0.0%)10 (17.9%)0.19
Atrial fibrillation10 (14.9%)0 (0.0%)10 (17.9%)0.19
Hemoglobin (g/dL)14.0 ± 2.013.4 ± 2.614.1 ± 1.90.30
eGFR (mL/min/1.73 m2)63.9 ± 24.445.1 ± 31.367.6 ± 21.20.004
LDL cholesterol (mg/dL)92 ± 2987 ± 1993 ± 300.48
Glycated hemoglobin (%)6.0 ± 0.66.1 ± 0.56.0 ± 0.60.34
Log-BNP3.52 ± 1.474.49 ± 1.793.32 ± 1.330.01
Medical treatment
Antiplatelet39 (58.2%)6 (54.6%)33 (58.9%)1.00
Statin40 (59.7%)7 (63.6%)33 (58.9%)1.00
β-blocker23 (34.3%)4 (36.4%)19 (33.9%)1.00
ACE-i or ARB28 (41.8%)5 (45.5%)23 (41.1%)1.00
Calcium channel blocker36 (53.7%)6 (54.6%)30 (53.6%)1.00
Nitrate10 (14.9%)3 (27.3%)7 (12.5%)0.35
ACE-i, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP, brain natriuretic peptide; CMD, coronary microvascular dysfunction; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; MI, myocardial infarction.
Table 4. Physiological findings under intracoronary papaverine-induced hyperemia.
Table 4. Physiological findings under intracoronary papaverine-induced hyperemia.
VariableAll
(n = 67)
CMD
(n = 11)
Non-CMD
(n = 56)
p Value
Resting Pd/Pa0.93 ± 0.030.92 ± 0.030.93 ± 0.020.17
FFR0.85 ± 0.070.87 ± 0.060.85 ± 0.070.49
FFR ≤0.8016 (23.9%)3 (27.3%)13 (23.2%)0.72
Resting Tmn0.93 ± 0.490.96 ± 0.750.93 ± 0.420.86
Hyperemic Tmn0.20 ± 0.110.34 ± 0.180.18 ± 0.07<0.001
BRI79.7 ± 41.992.4 ± 74.077.2 ± 32.70.28
IMR14.9 ± 9.928.0 ± 16.512.3 ± 5.1<0.001
IMR ≥258 (11.9%)8 (72.7%)0 (0.0%)<0.001
CFR5.4 ± 2.92.8 ± 2.05.9 ± 2.8<0.001
CFR <2.06 (9.0%)6 (54.6%)0 (0.0%)<0.001
RRR6.4 ± 3.63.2 ± 2.37.0 ± 3.4<0.001
MRR7.1 ± 3.93.5 ± 2.47.8 ± 3.7<0.001
BRI, baseline resistance index; CFR, coronary flow reserve; CMD, coronary microvascular dysfunction; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MRR, microvascular resistance reserve; Pd/Pa, ratio of distal coronary pressure to aortic pressure; RRR, resistive reserve ratio; Tmn, mean transit time.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yamazaki, T.; Saito, Y.; Yamashita, D.; Kitahara, H.; Kobayashi, Y. Factors Associated with Impaired Resistive Reserve Ratio and Microvascular Resistance Reserve. Diagnostics 2023, 13, 950. https://doi.org/10.3390/diagnostics13050950

AMA Style

Yamazaki T, Saito Y, Yamashita D, Kitahara H, Kobayashi Y. Factors Associated with Impaired Resistive Reserve Ratio and Microvascular Resistance Reserve. Diagnostics. 2023; 13(5):950. https://doi.org/10.3390/diagnostics13050950

Chicago/Turabian Style

Yamazaki, Tatsuro, Yuichi Saito, Daichi Yamashita, Hideki Kitahara, and Yoshio Kobayashi. 2023. "Factors Associated with Impaired Resistive Reserve Ratio and Microvascular Resistance Reserve" Diagnostics 13, no. 5: 950. https://doi.org/10.3390/diagnostics13050950

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop